|1.||Rodenhuis, S: 8 articles (04/2006 - 01/2001)|
|2.||Finlay, Jonathan L: 7 articles (07/2015 - 11/2003)|
|3.||Yu, Jing: 5 articles (11/2015 - 01/2011)|
|4.||Ren, Jun: 5 articles (11/2015 - 01/2011)|
|5.||Dunkel, Ira J: 5 articles (07/2015 - 05/2004)|
|6.||Wang, Xiaoli: 4 articles (11/2015 - 01/2011)|
|7.||Zhou, Xinna: 4 articles (11/2015 - 01/2011)|
|8.||Miller, Douglas C: 4 articles (07/2015 - 05/2004)|
|9.||Bacigalupo, A: 4 articles (03/2010 - 12/2000)|
|10.||Rodenhuis, Sjoerd: 4 articles (02/2009 - 09/2002)|
10/01/1985 - "Thiotepa, until recently the most commonly used agent, completely eradicates all obvious tumor in approximately 30 per cent of patients, and it is effective in preventing subsequent tumor. "
09/01/2000 - "Given the chemosensitivity of these neoplasms, a phase II study of high-dose thiotepa (HDT) was performed to evaluate the efficacy of this drug in this particular subset of pediatric tumors. "
11/01/1991 - "The data indicate that high-dose thiotepa is effective in several types of recurrent pediatric solid tumors, and merits further evaluation in combination regimens."
08/01/1990 - "High-dose thiotepa with autologous bone marrow rescue is a new and promising treatment modality in several kinds of solid tumors. "
01/01/1989 - "Thiotepa is moderately effective in delaying the development of subsequent low grade tumors when used for prophylaxis. "
|2.||Breast Neoplasms (Breast Cancer)
12/01/2013 - "This is the largest retrospective cohort of breast cancer MC treated by intrathecal thiotepa ever reported. "
12/01/2013 - "Sixty-six patients have been treated with intrathecal thiotepa either as first line or second line of treatment for breast cancer MC. "
12/01/2013 - "The aim of our retrospective study is to describe survival and prognostic factors of breast cancer patients treated by intrathecal thiotepa. "
10/01/2013 - "Our previous work showed thiotepa could eradicate breast cancer stem cells. "
09/01/1994 - "From 1985 to 1990, 271 patients, aged 27-55 years, with stage IIb-IIIa breast cancer were randomized to receive either one or two courses of thiotepa 20 mg (i.m. "
|3.||Urinary Bladder Neoplasms (Bladder Cancer)
10/01/1978 - "Thio-tepa can be given safely in the immediate postoperative period and is effective in decreasing the recurrence rate of superficial bladder tumors."
01/01/2013 - "The efficacy of intravesical thiotepa was evaluated compared with administration of Bacille Calmette-Guérin (BCG) in non-muscle invasive bladder cancer. "
06/01/1994 - "This analysis confirms that the thiotepa regimens tested cannot be recommended for use outside clinical trials for patients with newly diagnosed superficial bladder cancer."
01/01/1989 - "BCG versus thiotepa in non-CIS, stage Ta, T1 bladder cancer: rationale and design of ECOG trial."
08/01/1988 - "In the current study at Veterans Administration Medical Center, three of the four patients who received Thiotepa have had recurrences of their bladder tumors or positive urine cytology. "
12/01/1991 - "On the basis of a Phase I reevaluation of thio-TEPA in which 3 of 9 patients with ovarian carcinoma responded, we instituted a Phase II study at high doses. "
12/01/1991 - "Phase II trial of thio-TEPA in relapsed and refractory ovarian carcinoma."
04/01/1977 - "In view of increasing topical use of various chemotherapeutic agents for bladder carcinoma, an experimental study concerning the effect of triethylene thiophosphoramide (Thio-Tepa) on cell kinetics of bladder carcinoma cells was performed, working on an established cell line of human bladder carcinoma. "
01/01/1996 - "Among the other 31 patients who received PBPCs (all of whom also received thioTEPA prior to CPA and cDDP), there were 4 deaths, all involving patients with refractory ovarian carcinoma. "
01/01/1987 - "Single and repeated dose pharmacokinetics of thio-TEPA in patients treated for ovarian carcinoma."
12/01/2014 - "Thiotepa-based conditioning followed by HSCT may be effective in most CNS lymphoma patients, with a manageable toxicity profile. "
12/01/2014 - "Effectiveness and safety of thiotepa as conditioning treatment prior to stem cell transplant in patients with central nervous system lymphoma."
02/01/1990 - "High-dose combination chemotherapy with thiotepa and autologous hematopoietic stem cell reinfusion in the treatment of patients with relapsed refractory lymphomas."
10/01/1976 - "Eleven patients with meningeal leukemia, lymphoma, or ependymoma were treated with intrathecal thio-TEPA in doses from 1 to 10 mg/m2 of body surface area. "
04/01/2003 - "Furthermore, this small series suggests that high-dose chemotherapy for PCNSL should include drugs that penetrate the CNS such as busulfan and thiotepa rather than standard lymphoma regimens such as BEAM."
|6.||Etoposide (VP 16)
|1.||Drug Therapy (Chemotherapy)
|3.||Stem Cell Transplantation
|4.||Transplantation (Transplant Recipients)